Long-acting Therapeutics

Long-acting therapeutics are emerging as gamechangers in healthcare by offering a simpler yet effective way of administering medicines that frees patients from daily pills, helps them stay on treatment & reduces burden on health systems. MPP is working on an access plan to ensure that as these products get developed, they are available to everyone, everywhere and at the same time.

Expanding Access to Long-acting Therapeutics in LMICs

The field of long-acting (LA) therapeutics is emerging as the next frontier for healthcare management. By offering sustained and controlled release of medicines, LA technologies make it easier to achieve optimal dosing targets with less frequent administrations of treatment, thus offering support for smoother condition management.

Long-acting therapeutics are already blooming in the fields of contraception, harm reduction, diabetes and mental health, and the first products targeting infectious diseases prevention and treatment are already available in some markets. The technologies include an array of delivery systems for new drug formulations, such as transdermal patches, implants, depots, intra-uterine devices, some of which have versatile characteristics and could accommodate a range of medicines and more than one medicine at a time.

The LA therapeutics landscape is particularly dynamic as several stakeholders are joining efforts to accelerate the development of LA products in many health areas. It includes funders, product development partnerships, industry, academia, civil society and patient groups, policy makers, as well as specialist consortia and working groups.

A concerted access plan is essential to make sure these new products are available at the same time to all who need them globally, including affordable and adapted options for those living in low- and middle-income countries (LMICs). To date, LMICs tend to lag behind when it comes to access to new health solutions, and the Medicines Patent Pool is putting efforts to reduce that lag as much as possible, in collaboration with key stakeholders.

Long-acting therapeutics combine one or more active pharmaceutical ingredients formulated into a technology to deliver treatment or prophylaxis. This generally results in a complex multi-layered IP protection that complicates access to these LA options. The Medicines Patents Pool (MPP), with its proven model in voluntary licensing and IP-related facilitation is a natural player in this landscape.

Since 2019, MPP is leveraging its expertise in in- and out-licensing, identification of development and commercialisation partners, technology transfer facilitation, and advocacy within most active LA working groups to adopt global access guidelines, thus contributing to making these technologies available and affordable to everyone, everywhere.

MPP’s work in the long-acting therapeutics space includes:

  • Voluntary licensing among other types of public-health oriented agreements with innovators and other stakeholders in the long-acting space to ensure accelerated access to LA technologies and their applications in LMICs

Access MPP’s licence agreements

  • Piloting of a free online database for long-acting technologies patents and licences with the objective of enabling information exchange and collaboration

Know more about LAPaL, MPP’s long-acting technologies patents and licences database

  • Synergising efforts in the LA space by advocating for the need of accessible products and technologies, facilitation of collaborations and support for active pharmaceutical ingredients sourcing through partners network where possible

Know more about MPP’s activities to foster access to LA technologies in LMICs

The First Access-Oriented Licences for Long-Acting Technologies

As a proof of concept of the feasibility and relevance of early licensing in the long-acting space, MPP is working closely with three Unitaid grantees for long-acting projects that aim to accelerate the development of existing medicines into LA versions to prevent malaria and TB and treating HIV and hepatitis C.

Intellectual property within these projects will be protected by patents that are being licensed to MPP. MPP’s work in LA therapeutics will facilitate development, secure commercial partners and ensure that products become accessible and affordable where they are needed, in a timely manner.

These licences represent a milestone as first ever access-oriented agreements for long-acting technologies, specifically tailored for expanded access to infectious diseases life-saving commodities

The three Unitaid investments where MPP will play a key role are:

  • LONGEVITY project led by University of Liverpool, which is developing long-acting injectable formulations of drugs for malaria and TB prevention, and a cure for hepatitis C. A licence for the outcome of this project was signed with Tandem Nano Ltd. in September 2021.

Access the Tandem Nano-MPP licence

  • GLAD project led by the University of Washington, that aims to transform HIV treatment oral combination regimens based on dolutegravir into an injectable that has a lasting effect of one to three months. A licence for the outcome of this project was signed with the University of Washington in December 2021.

Access the UoW-MPP licence

  • IMPACT project led by MedinCell, which will develop a malaria prevention vector control tool that could be delivered sub-cutaneously for three months to adults in high-risk areas.

Related Events & Reports

News & Press Releases » Events

MPP at the LEAP pre-CROI workshop

19 March 2021

News & Press Releases » Events

MPP co-sponsored with Medincell a conference on Long-Acting Injectables and Implantables

La Jolla - San Diego

08 February 2020

MPP Logo

Subscribe to our Newsletter

Founded & funded by

Unitaid Logo

Other funders